Designing and Expression of an Immunogenic Poly-Epitope Protein from Streptococcus pneumoniae An immunogenic protein from S. pneumoniae
Trends in Peptide and Protein Sciences,
Vol. 6 (2021),
24 February 2021
,
Page 1-5 (e4)
https://doi.org/10.22037/tpps.v6i.35510
Abstract
A well-designed vaccine against Streptococcus pneumonia, a respiratory pathogen, by immunoinformatics approaches can lead to an effective mucosal and local immunity in the upper respiratory tract. In this study, we chose virulence proteins from different strains of S. pneumonia (Pneumolysin, Neuraminidase, Zink-Metalloproteinase, and Hydrolase) and designed a new multi-epitope construct by properly linking the individual predicted T and B cell specific epitopes. Then, the polytope, named PNEU, was expressed in Escherichia coli as a prokaryotic system. Through computational calculations, PNEU polypeptide with 216 aa has the theoretical pI 8.04 and instability index 33.63, which show that it is a stable and soluble protein. Also, the 3D structure of PNEU was predicted by Phyre2 server with 96.0% confidence. In conclusion, PNEU protein can be considered as a stable and soluble immunogenic protein, which may be efficiently used for immunity stimulation in laboratory animals, investigated in future studies.
Highlights
- The poly epitope PNEU protein is a vaccine candidate for Streptococcus pneumonia.
- PNEU is a stable and soluble protein.
- PNEU shows a proper folding through in silico 3D structure prediction.
- PNEU protein expression in prokaryotic systems was confirmed.
- Immunoinformatics
- In silico design
- Poly-epitope
- Streptococcus pneumoniae
- Subunit vaccine
How to Cite
References
AlonsoDeVelasco, E., Verheul, A.F.M., Verhoef, J. and H. Snippe, (1995). "Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines." Microbiology Reviews, 59(4) :591–603.
Bahrami, A.A., Bandehpour, M., Khalesi, B. and B. Kazemi, (2020). "Computational design and analysis of a poly-epitope fusion protein: a new vaccine candidate for Hepatitis and Poliovirus." International Journal of Peptide Research and Therapeutics, 26(1):389-403.
Chiavolini, D., Memmi, G., Maggi, T., Iannelli, F., Pozzi, G. and M.R. Oggioni, (2003). "The three extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different impact on virulence in mice." BMC Microbiology, 3: 14 (2003).
Cui, L.M., Zhang, K., Ma, D.J., Liu, S.P. and X.W. Zhang, (2014). "Protein expression under sustained activation of signal transducer and activator of transcription-3 in diethylnitrosamine-induced rat liver carcinogenesis." Oncology Letters, 8(2): 608–614.
Daniels, C.C., Rogers, P.D. and C.M. Shelton,(2016). "A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens." Journal of Pediatric Pharmacology and Therapeutics, 21(1): 27–35.
Da Silva, C.A., Chalouni, C., Williams, A., Hartl, D., Lee, C.G. and J.A. Elias, (2009). "Chitin is a size-dependent regulator of macrophage TNF and IL-10 production." Journal of Immunology,182(6): 3573–3582.
Da Silva, C.A., Pochard, P., Lee, C.G. and J.A. Elias, (2010). "Chitin particles are multifaceted immune adjuvants." American Journal of Respiratory Critical Care Medicine, 182(12):1482–1491.
Da Silva, C.A., Hartl, D., Liu, W., Lee, C.G. and J.A. Elias, (2008). "TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation." Journal of Immunology, 181(6): 4279–4286.
Dorosti, H., Eslami, M., Negahdaripour, M., Ghoshoon, M.B., Gholami, A., Heidari, R., Dehshahri, A., Erfani, N., Nezafat, N. and Y.Ghasemi, (2019). "Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine." Journal of Biomolecular Structure and Dynamics, 37(13): 3524–3535.
Fang, L., Wolmarans, B., Kang, M., Jeong, K.C. and A.C. Wright, (2015). "Application of chitosan microparticles for reduction of vibrio species in seawater and live oysters (Crassostrea virginica)." Applied Environmental Microbiology, 81(2): 640–647.
Genschmer, K.R., Accavitti-Loper, M.A. and D.E. Briles, (2013). "A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA)." Vaccine, 32(1): 39–47.
Khan, N. and A.T. Jan, (2017). "Towards Identifying Protective B-Cell Epitopes: The PspA Story." Frontier Microbiology, 8: 742.
Mellroth, P., Daniels, R., Eberhardt, A., Rönnlund, D., Blom, H., Widengren, J., et al., (2012). "LytA, major autolysin of Streptococcus pneumoniae, requires access to nascent peptidoglycan." Journal of Biological Chemistry, 287(14 ): 11018–11029.
Sharapova, Y., Suplatov, D. and V. Švedas, (2018). "Neuraminidase A from Streptococcus pneumoniae has a modular organization of catalytic and lectin domains separated by a flexible linker." FEBS Journal, 285(13): 2428–2445.
Ritchie, N.D., Ritchie, R., Bayes, H.K., Mitchell, T.J. and T.J. Evans, (2018). "IL-17 can be protective or deleterious in murine pneumococcal pneumonia." PLoS Pathogens, 14(5) :e1007099.
Wadhwani, A. and V. Khanna, (2016). "In silico identification of novel potential vaccine candidates in Streptococcus pneumoniae." Global Journal of Technology & Optimization, 7: 6.
Weiser, J.N., Ferreira, D.M. and J.C. Paton,(2018). "Streptococcus pneumoniae: Transmission, colonization and invasion." Nature Reviews. Microbiology, 16(6): 355–367.
- Abstract Viewed: 349 times
- PDF Downloaded: 181 times